17,261 trials
Sickle Cell Disease
Primary: Percentage of Participants With Overall Survival (OS) at 2 Years After Biologic Assignment — 89; 94 percentage of participants
VHL Gene Mutation · VHL · VHL Syndrome
Primary: Overall Response Rate (ORR) in VHL Disease-Associated ccRCC Tumors — 0.0 Percentage of Participants
Relapsed or Refractory EBV-and CD30-positive Lymphomas
Primary: To Evaluate the Overall Response Rate (ORR) of Brentuximab Vedotin in EBV- and CD30-positive Lymphomas — 12 Participants
COVID-19
Primary: Percentage of Participants With Sustained Nasopharyngeal (NP) Swab Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Ribonucleic Acid (RNA) < Lower Limit of…
Breast Cancer
Primary: Progression-free Survival — 21.8; 12.8 months — p=0.003
Atrial Fibrillation
Primary: The Maximum Reduction in Ventricular Rate, Measured on Holter Monitoring, Within 60 Minutes From Drug Administration. — 135.5; 130.3; 130.7; 95.2 bpm — p=<0.0001
Gastric Cancer
Primary: Disease Control Rate — 9 Participants
Cervical Cancer
Primary: Objective Response Rate (ORR) — 17.7 Percentage of Participants
Invasive Breast Carcinoma · Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7
Primary: RCB Status — 4; 6; 8; 6 Participants
Parkinson Disease
Primary: Gait Velocity — 1.20; 1.22; 1.03; 1.07 meters/second
Antipsychotic-induced Weight Gain (AIWG)
Primary: Change From Baseline in Body Weight at Week 12 for 600 mg Miricorilant Versus Placebo — -0.98; -1.08 kg — p=0.8511
Elranatamab · Myeloma · Multiple Myeloma
Primary: Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) — 1 Participants
Adult T-Cell Lymphoma (ATL)
Primary: Objective Response Rate — 7 Participants
Breast Cancer
Primary: Complication Rate — 15; 20 percentage of participants
Peripheral T-Cell Lymphoma (PTCL)
Primary: Objective Response Rate — 21 Participants